Intetumumab

英妥木单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameIntetumumab
Drug Alias NameCNTO-095CNTO-95
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionIntegrin alpha-V/beta-5 antagonistsIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-5Integrin alpha-V/beta-3
Therapy Area/IndicationsProstatic NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen-Cilag Farmaceutica SrlAlthea Technologies IncBeOne Medicines Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG